J. A. Kanis, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report, Osteoporos Int, vol.4, issue.6, pp.368-81, 1994.

H. Autorité-de-santé, Ostéodensitométrie sur 2 sites par méthode biphotonique, 2006.

K. Briot, B. Cortet, T. Thomas, M. Audran, H. Blain et al., Actualisation 2012 des recommandations françaises du traitement médicamenteux de l'ostéoporose postménopausique, Rev Rhum, vol.79, issue.3, pp.264-74, 2012.

H. Autorité-de-santé, Les médicaments de l'ostéoporose -Fiche Bon Usage du médicament, 2014.

, Agence française de sécurité sanitaire des produits de santé. Traitement médicamenteux de l'osteoporose post-ménauposique, 2006.

A. Svedbom, E. Hernlund, M. Ivergård, J. Compston, C. Cooper et al., Osteoporosis in the European Union: a compendium of country-specific reports, Arch Osteoporos, vol.8, issue.1-2, p.137, 2013.

E. M. Curtis, R. J. Moon, E. M. Dennison, N. C. Harvey, and C. Cooper, Recent Advances in the Pathogenesis and Treatment of Osteoporosis, Clin Med Lond Engl, vol.16, issue.4, pp.360-364, 2016.

F. Retornaz, V. Seux, and J. Soubeyrand, Ostéoporoses secondaires en médecine interne, Rev Médecine Interne, vol.25, pp.543-51, 2004.

H. Autorité-de-santé, Évaluation et prise en charge des personnes âgées faisant des chutes répétées, 2009.

D. Curran, M. Maravic, P. Kiefer, V. Tochon, and P. Fardellone, Epidemiology of osteoporosis-related fractures in France: a literature review, Jt Bone Spine Rev Rhum, vol.77, issue.6, pp.546-51, 2010.

S. Ministère-des, L. De, and . Santé, L'état de santé de la population en France -rapport, 2008.

M. Maravic, C. L. Bihan, P. Landais, and P. Fardellone, Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database, Osteoporos Int, vol.16, issue.12, pp.1475-80, 2005.

B. Thélot, L. Lasbeur, and G. Pédrono, La surveillance épidémiologique des chutes chez les personnes âgées, Bull Epidémiol Hebd, pp.328-363, 2017.

M. Rousière, De l'importance de prendre en charge l'ostéoporose. Presse Médicale, vol.40, pp.900-909, 20111.

D. Bliuc, N. D. Nguyen, V. E. Milch, T. V. Nguyen, J. A. Eisman et al., Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women, JAMA, vol.301, issue.5, pp.513-534, 2009.

C. Cooper, The crippling consequences of fractures and their impact on quality of life, Am J Med, vol.103, issue.2, pp.12-21, 1997.

P. P. Geel-tacm-van,-helden-s-van,-geusens, B. Winkens, and G. Dinant, Clinical subsequent fractures cluster in time after first fractures, Ann Rheum Dis, vol.68, issue.1, pp.99-102, 2009.

E. Lespessailles, F. E. Cotté, C. Roux, P. Fardellone, F. Mercier et al., Prévalence et caractéristiques de l'ostéoporose dans la population générale en France : l'étude Instant, Rev Rhum, vol.76, issue.7, pp.685-92, 2009.

L. Giangregorio, A. Papaioannou, A. Cranney, N. Zytaruk, and J. D. Adachi, Fragility Fractures and the Osteoporosis Care Gap: An International Phenomenon, Semin Arthritis Rheum, vol.35, issue.5, pp.293-305, 2006.

S. Parikh, H. Mogun, J. Avorn, and D. H. Solomon, Osteoporosis Medication Use in Nursing Home Patients With Fractures in 1 US State, Arch Intern Med, vol.168, issue.10, pp.1111-1116, 2008.

B. Cortet, Diagnostic de l'ostéoporose: quels examens biologiques faut-il faire ? Presse Médicale, vol.35, pp.1540-1542, 2006.

H. Autorité-de-santé, Utilité clinique du dosage de la vitamine D -Rapport d'évaluation, 2013.

, PROTELOS (ranélate de strontium) : prochain arrêt de commercialisation

. Vidal, , 2017.

G. A. Wells, A. Cranney, J. Peterson, M. Boucher, B. Shea et al., Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst Rev, issue.1, p.1155, 2008.

S. T. Harris, N. B. Watts, H. K. Genant, C. D. Mckeever, T. Hangartner et al., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group, JAMA, vol.282, issue.14, pp.1344-52, 1999.

D. M. Black, P. D. Delmas, R. Eastell, I. R. Reid, S. Boonen et al., Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis, N Engl J Med, vol.356, issue.18, pp.1809-1831, 2007.

R. M. Neer, C. D. Arnaud, J. R. Zanchetta, R. Prince, G. A. Gaich et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, vol.344, issue.19, pp.1434-1475, 2001.

K. Briot, 2018 update of french recommendations of the management of postmenopausal osteoporosis, Joint Bone Spine, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01808094

S. R. Cummings, S. Martin, J. Mcclung, M. R. Siris, E. S. Eastell et al., Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, vol.361, issue.8, pp.756-65, 2009.

J. A. Cauley, J. Robbins, Z. Chen, S. R. Cummings, R. D. Jackson et al., Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density: The Women's Health Initiative Randomized Trial, JAMA, vol.290, issue.13, pp.1729-1767, 2003.

B. Ettinger, D. M. Black, B. H. Mitlak, R. K. Knickerbocker, T. Nickelsen et al., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, JAMA, vol.282, issue.7, pp.637-682, 1999.

H. Autorité-de-santé, Prise en charge de l'ostéoporose : la HAS publie une synthèse à destination des professionnels de santé, 2007.

J. A. Kanis, E. V. Mccloskey, H. Johansson, C. Cooper, R. Rizzoli et al., European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos Int, vol.24, issue.1, pp.23-57, 2013.

J. Lambert, Dépistage et traitement de l'ostéoporose après la survenue d'une fracture: résultats d'une étude conduite en population générale en Basse-Normandie, 2015.

Y. Rolland, G. Kan, S. Hermabessiere, S. Gerard, S. Guyonnet-gillette et al., Descriptive study of nursing home residents from the REHPA network, J Nutr Health Aging, vol.13, issue.8, pp.679-83, 2009.

M. Maravic, P. Taupin, P. Landais, and C. Roux, Change in hip fracture incidence over the last 6 years in France, Osteoporos Int, vol.22, issue.3, pp.797-801, 2011.

B. J. Zarowitz, L. Cheng, A. C. , O. Shea, T. Stolshek et al., Osteoporosis Prevalence and Characteristics of Treated and Untreated Nursing Home Residents With Osteoporosis, J Am Med Dir Assoc, vol.16, issue.4, pp.341-349, 2015.

C. Klop, D. Gibson-smith, P. Elders, P. Welsing, H. Leufkens et al., Antiosteoporosis drug prescribing after hip fracture in the UK, Osteoporos Int, vol.26, issue.7, pp.1919-1947, 2000.

J. Flais, G. Coiffier, L. Noach, J. , A. Faccin et al., 17 -Faible prévalence du traitement de l'ostéoporose chez des patients avec une récidive de fracture ostéoporotique majeure, Rev Rhum, vol.83, p.52, 2016.

B. Merle, R. Chapurlat, E. Vignot, T. Thomas, J. Haesebaert et al., Post-fracture care: do we need to educate patients rather than doctors? The PREVOST randomized controlled trial, Osteoporos Int, vol.28, issue.5, pp.1549-58, 2017.

F. Erny, A. Auvinet, C. M. Lin, D. Pioger, A. Haguenoer et al., Management of osteoporosis in women after forearm fracture: Data from a French health insurance database, Joint Bone Spine, vol.82, issue.1, pp.52-57, 2015.

G. Coiffier, O. Niclet, J. D. Albert, and P. Guggenbuhl, Les médecins généralistes connaissent-ils les recommandations de la Société Française de Rhumatologie pour la prise en charge de l'ostéoporose post-ménopausique ? Résultats d'une enquête auprès de 163 médecins généralistes exerçant en Bretagne, Rev Rhum, vol.83, pp.272-275, 2016.

D. Briançon, J. De-gaudemar, and R. Forestier, La prise en charge médicale de l'ostéoporose après fractures périphériques chez la femme de plus de 50 ans, Rev Rhum, vol.71, issue.3, pp.216-225, 2004.

S. Daniel, H. , J. Stephen, S. , B. Natalie et al., Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between, J Bone Miner Res, vol.29, issue.9, pp.1929-1966, 2002.

S. Roux, M. Beaulieu, M. Beaulieu, F. Cabana, and G. Boire, Priming Primary Care Physicians to Treat Osteoporosis After a Fragility Fracture: An Integrated Multidisciplinary Approach, J Rheumatol, vol.40, issue.5, pp.703-714, 2013.

S. E. Andrade, S. R. Majumdar, K. A. Chan, D. Buist, A. S. Go et al., Low Frequency of Treatment of Osteoporosis Among Postmenopausal Women Following a Fracture, Arch Intern Med, vol.163, issue.17, pp.2052-2059, 2003.

, Fractures liées à une fragilité osseuse : prévention -Premiers Choix Prescrire, actualisation septembre, vol.37, p.929, 2017.

D. L. Kendler, F. Marin, C. Zerbini, L. A. Russo, S. L. Greenspan et al., Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial, The Lancet, vol.391, pp.230-270, 2018.

C. Breysse, P. Guillot, and G. Berrut, Study of vitamin D supplementation in people over 65 years in primary care, Gériatrie Psychol Neuropsychiatr Viellissement, issue.2, pp.123-132, 2015.

A. Bouvet, B. Sabatier, V. Savoldelli, T. Caruba, and J. Pouchot, Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture, J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis, vol.20, issue.6, pp.347-355, 2014.

H. K. Kamel, M. S. Hussain, S. Tariq, H. M. Perry, and J. E. Morley, Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture, Am J Med, vol.109, issue.4, pp.326-334, 2000.

G. Cousin, S. Mast, and M. , Les médecins hommes et femmes interagissent de manière différente avec leurs patients : pourquoi s'en préoccuper, Rev Med Suisse, vol.6, pp.1444-1451, 2010.

C. Simonelli, K. Killeen, S. Mehle, and L. Swanson, Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons, Mayo Clin Proc, vol.77, issue.4, pp.334-342, 2002.

G. Grelier, Pratiques, déterminants et obstacles à la prise en charge de l'ostéoporose postménopausique après fracture par des médecins généralistes sarthois, 2014.

M. Boudreau-denise, Y. Onchee, B. Akhila, W. Heidi, G. Andreas et al., A Survey of Women's Awareness of and Reasons for Lack of Postfracture Osteoporotic Care, J Am Geriatr Soc, vol.65, issue.8, pp.1829-1864, 2017.

I. Polymedini, S. Carballo, and A. Trombetti, Risque d'ostéonécrose des maxillaires avec l'utilisation des bisphosphonates, Rev Médicale Suisse, vol.10, pp.1930-1934, 2014.

D. H. Solomon, E. Mercer, S. B. Woo, J. Avorn, S. Schneeweiss et al., Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges, Osteoporos Int, vol.24, issue.1, pp.237-281, 2013.

, APOROSE | Aide à la Prise en charge de l'OstéopoROSE, 2018.

A. Vandenbroucke, F. Luyten, J. Flamaing, and E. Gielen, Pharmacological treatment of osteoporosis in the oldest old, Clin Interv Aging, vol.12, pp.1065-77, 2017.

A. Papaioannou, N. Santesso, S. N. Morin, S. Feldman, J. D. Adachi et al., Recommendations for preventing fracture in long-term care, Can Med Assoc J, vol.187, issue.15, pp.1135-1179, 2015.

P. Mitchell, K. Åkesson, M. Chandran, C. Cooper, K. Ganda et al., Implementation of Models of Care for secondary osteoporotic fracture prevention and orthogeriatric Models of Care for osteoporotic hip fracture, Best Pract Res Clin Rheumatol, vol.30, issue.3, pp.536-58, 2016.

K. Ganda, M. Puech, J. S. Chen, R. Speerin, J. Bleasel et al., Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis, Osteoporos Int, vol.24, issue.2, pp.393-406, 2013.

, Groupe de recherche et d'information sur les ostéoporoses. Club Filières et Fractures, 2018.

E. A. Little and M. P. Eccles, A systematic review of the effectiveness of interventions to improve postfracture investigation and management of patients at risk of osteoporosis, Implement Sci IS, vol.5, p.80, 2010.

K. V. Grigoryan, H. Javedan, and J. L. Rudolph, Ortho-Geriatric Care Models and Outcomes in Hip Fracture Patients: A Systematic Review and Meta-Analysis, J Orthop Trauma, vol.28, issue.3, pp.49-55, 2014.

H. Autorité-de-santé, Orthogériatrie et fracture de la hanche, 2017.

J. Boddaert, J. Cohen-bittan, F. Khiami, Y. L. Manach, M. Raux et al., Postoperative Admission to a Dedicated Geriatric Unit Decreases Mortality in Elderly Patients with Hip Fracture, PLOS ONE, vol.9, issue.1, p.83795, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01344762

A. M. Schott, C. Cormier, D. Hans, F. Favier, E. Hausherr et al., How Hip and Whole-Body Bone Mineral Density Predict Hip Fracture in Elderly Women: The EPIDOS Prospective Study, Osteoporos Int, vol.8, issue.3, pp.247-54, 1998.

G. Coiffier, T. Couchouron, G. Larroche, J. Bouget, H. Thomazeau et al., Impact du recours systématique au médecin traitant sur la réalisation d'une densitométrie osseuse et la mise en route d'un traitement après la survenue d'une fracture à bas niveau d'énergie dépistée dès les urgences. Étude prospective monocentrique sur 434 patients suivis six mois, Rev Rhum, vol.80, issue.6, pp.577-82, 2013.

T. D. Rozental, E. C. Makhni, C. S. Day, and M. L. Bouxsein, Improving Evaluation and Treatment for Osteoporosis Following Distal Radial Fractures: A Prospective Randomized Intervention, J Bone Jt Surg-Am, vol.90, issue.5, pp.953-61, 2008.

, Annexe 6 : recommandation Afssaps, 2006.

, Agence française de sécurité sanitaire des produits de santé, 2006.

, Annexe 8 : fiche « bon usage du médicament » HAS 2014 en cas de fracture ostéoporotique 10

H. Autorité-de-santé, Les Médicaments de L'ostéoporose -Fiche Bon Usage Du Médicament

, HAS, 2014.